CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...